AI
Friday, June 08, 2007 3:31:40 PM
VRUS
Sorry, not really. There are plenty of examples of molecules with identical mechanisms of action, very similar structures, and disparate safety and efficacy results. For example, statins, Cox-2 inhibitors, etc. As I said, adding a fluorine onto anything that size is likely to alter its biochemical properties substantially.
Anyway, it's not that important. What is important is that the company is *very* cheap for the pipeline.
PS: You're disobeying your own rule about including the ticker in each message. I'm the only one who follows the rules around here.
Sorry, not really. There are plenty of examples of molecules with identical mechanisms of action, very similar structures, and disparate safety and efficacy results. For example, statins, Cox-2 inhibitors, etc. As I said, adding a fluorine onto anything that size is likely to alter its biochemical properties substantially.
Anyway, it's not that important. What is important is that the company is *very* cheap for the pipeline.
PS: You're disobeying your own rule about including the ticker in each message. I'm the only one who follows the rules around here.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
